ImmunoCellular Therapeutics (OTCBB:IMUC), said Wednesday that president and CEO Manish Singh will be presenting at the 19th Annual Future Leaders Biotech Industry Conference in the Millennium Broadway Hotel & Conference Center in New York City.
ImmunoCellular will be presenting on Friday, April 20th, at 2:30 pm EST in presentation room 302/303.
The Annual Future Leaders in the Biotech Industry Conference brings
the industry’s top financial professionals together with an agenda
designed to meet the current investment climate.
Presenting companies will showcase their science, detail their unpartnered assets and upcoming milestones.
IMUC’s lead product candidate ICT-107 is currently in a randomized
phase II trial at multiple centres in the U.S. ICT-107 is a dendritic
cell-based vaccine targeting multiple tumour-related antigens for
glioblastoma, a malignant brain tumour.
This is done by removing dendritic cells from a patient, loading them
with the tumour-related antigens, and re-injecting them back into the
patient's body to trigger an immune response against cancer cells
exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen, IMUC’s
vaccine tracks multiple different antigens found on cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour
cells, and lead to cancer’s re-growth after chemotherapy. It is believed
that destroying the cancer stem cells will allow for longer survival,